Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005227235
Thu, 09.12.2021
Biotest AG
PRESS RELEASE
Biotest Supervisory Board appoints new Management Board member
- Dr Jörg Schüttrumpf appointed to the Board as Chief Scientific Officer (CSO)
- Development of trimodulin and Fibrinogen to be accelerated
- Additional phase III trial with Covid-19 patients
Dreieich, 9 December 2021. At its meeting today, the Supervisory Board of Bi [ … ]
Wed, 08.12.2021
Biotest AG
PRESS RELEASE
Biotest adjusts guidance
Demand for drug therapies with coagulation factors cannot keep up with the enormous growth of immunoglobulins
Biotest only produces coagulation factors in a sales-correlated manner and depreciates existing raw materials
Dreieich, 8 December 2021. Around the world, the demand for human blood plasma is curren [ … ]
Tue, 30.11.2021
Biotest AG
PRESS RELEASE
Biotest receives approval for Intratect(R) in France
Approval in last major European immunoglobulin market in which Biotest has not yet had approval
Biotest starts nationwide commercialisation for future sales growth of Intratect(R)
Immunoglobulin market in France has sales volume of 550 million EUR
Dreieich, 30 November 2021 Biot [ … ]
Thu, 25.11.2021
Biotest AG
PRESS RELEASE
Biotest AG opens seventh plasma collection centre in Czech Republic
- 27 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 25 November 2021. Biotest has received the operating license for its seventh plasma collection centre in Czech Republic from the country's national public health authority SUKL. Th [ … ]
Tue, 23.11.2021
Biotest AG
PRESS RELEASEBiotest accelerates trimodulin development in hospitalized COVID-19 patients with federal funding in the volume of 29 million EUR
- The German Federal Ministry of Education and Research (BMBF) and German Federal Ministry of Health (BMG) awarded Biotest's trimodulin project with financial support in the volume of €29 million
- The fun [ … ]
Tue, 16.11.2021
Biotest AG
PRESS RELEASE
Cytotect CP(R) Biotest activates immune cells that are crucial to control Cytomegalovirus
Cytomegalovirus (CMV) leads to severe complications in immunocompromised patients, particularly after transplantation
Antiviral drugs suppress the production of new CMV particles in infected patients, but do not prevent initial infection of he [ … ]
Thu, 11.11.2021
Biotest AG
PRESS RELEASEBiotest increases sales by 9% in the first nine months 2021
- Increase in plasma collection centres to 26 in Europe
- Final manufacturing authorization for expansion project Biotest Next Level granted
- Guidance confirmed
Dreieich, 11 November 2021. The Biotest Group recorded revenues of € 371.4 million in the first nine months of [ … ]
Fri, 05.11.2021
Biotest AG
PRESS RELEASE
Joint reasoned statement of Biotest AG - Management Board and Supervisory Board recommend to accept takeover offer of GRIFOLS, S.A.
Dreieich, 5 November 2021. Today, the Management Board and the Supervisory Board of Biotest AG ("Biotest") have published their joint reasoned statement pursuant to Section 27 of the German Securities A [ … ]
Mon, 11.10.2021
Biotest AG
PRESS RELEASE
Biotest identifies a benefit with trimodulin in a relevant subgroup of hospitalised COVID-19 patients
- Complete data set from the phase II ESsCOVID trial analysed
- Post hoc subgroup analyses revealed a medical relevant benefit in hospitalised COVID-19 patients with early systemic inflammation
- Biotest considers further clinical [ … ]
Wed, 15.09.2021
Biotest AG
PRESS RELEASE
Biotest announces the new Renate & Hans Schleussner Award for scientific research
Award's aim is promotion of innovative research in the field of therapies with (hyper-) immunoglobulins
In memory of the Schleussner family who founded Biotest, the new research award will be named the Renate & Hans Schleussner Award
€ 50,00 [ … ]